The risk of colorectal cancer development is lower in patients with MSH6 variants than in those with MLH1 or MSH2 variants, but the risk of endometrial cancer development in patients with MSH6 variants is equivalent to or higher than that in those with MLH1 or MSH2 variants. Here, MLH1 is linked to endometrial cancer.